Latest Content

Regeneron announces agreement with the U.S. Government to set drug prices similarly to foreign prices, along with providing a new gene therapy free to eligible U.S. patients.

Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.

Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry.

In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.

Early clinical data from the CHORD trial supported accelerated approval of the first gene therapy targeting OTOF-related hearing loss under the FDA Commissioner’s National Priority Voucher program.

In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.

FDA expands its approval of Tzield to children as young as one with stage 2 type 1 diabetes, extending the first disease-modifying therapy into an earlier, high-risk population to delay progression to insulin-dependent disease.

EVERSANA’s president discusses the evolving role of the Asembia conference, emerging commercialization trends, and what’s top of mind for pharma leaders this year.

FDA expands Dupixent approval to children aged 2–11 with chronic spontaneous urticaria, marking the first biologic option for this population and extending its reach across type 2 inflammatory diseases.

MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.

In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights which top-selling drugs are most at risk of supply shortages.

FDA has approved Merck’s Idvynso, introducing a differentiated, two-drug, non-INSTI, tenofovir-free HIV regimen that maintains viral suppression while offering a potentially more tolerable, simplified option for long-term patient management.

Amazon has launched a new GLP-1 weight management program through its One Medical network, integrating obesity treatment into primary care while expanding access to both telehealth services and a range of branded medications.